Table 2 Summary of safety data
EZ + simva 10/20 mg | Simva 40 mg | p-value | |
|---|---|---|---|
Number of patients (%) | N = 42 | N = 51 | |
With adverse events | 5 (12.5) | 10 (20.0) | 0.40008 |
With treatment-related adverse events | 3 (7.5) | 3 (6.0) | 0.9999 |
Discontinued due to adverse events | 1 (2.5) | 2 (4.0) | 0.9999 |
Discontinued due to treatment-related adverse events | 1 (2.5) | 2 (4.0) | 0.9999 |
Serious adverse events | 1* | 0 | 0.4518 |
ALT/AST ≥ 3 × upper limit of normal | 0 | 0 | -- |
CK ≥ 5-10 × upper limit of normal elevation | 0 | 0 | -- |